A detailed history of Soltis Investment Advisors LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Soltis Investment Advisors LLC holds 140,750 shares of GALT stock, worth $146,380. This represents 0.04% of its overall portfolio holdings.

Number of Shares
140,750
Holding current value
$146,380
% of portfolio
0.04%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 18, 2024

BUY
$2.04 - $2.86 $287,130 - $402,545
140,750 New
140,750 $387,000

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $61.8M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Soltis Investment Advisors LLC Portfolio

Follow Soltis Investment Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Soltis Investment Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Soltis Investment Advisors LLC with notifications on news.